DK3646854T3 - Sammensætninger til transfektion af mRNA i en celle og anvendelser deraf - Google Patents
Sammensætninger til transfektion af mRNA i en celle og anvendelser deraf Download PDFInfo
- Publication number
- DK3646854T3 DK3646854T3 DK18306417.9T DK18306417T DK3646854T3 DK 3646854 T3 DK3646854 T3 DK 3646854T3 DK 18306417 T DK18306417 T DK 18306417T DK 3646854 T3 DK3646854 T3 DK 3646854T3
- Authority
- DK
- Denmark
- Prior art keywords
- transfection
- mrna
- compositions
- cell
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000001890 transfection Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306417.9A EP3646854B1 (en) | 2018-10-30 | 2018-10-30 | Compositions for transfecting mrna into a cell and their applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3646854T3 true DK3646854T3 (da) | 2022-09-26 |
Family
ID=64572258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18306417.9T DK3646854T3 (da) | 2018-10-30 | 2018-10-30 | Sammensætninger til transfektion af mRNA i en celle og anvendelser deraf |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210386841A1 (da) |
| EP (1) | EP3646854B1 (da) |
| JP (1) | JP7477504B2 (da) |
| KR (1) | KR20210084511A (da) |
| CN (1) | CN112930172B (da) |
| AU (1) | AU2019373387B2 (da) |
| DK (1) | DK3646854T3 (da) |
| ES (1) | ES2927532T3 (da) |
| IL (1) | IL282579B2 (da) |
| PL (1) | PL3646854T3 (da) |
| PT (1) | PT3646854T (da) |
| SG (1) | SG11202103117RA (da) |
| WO (1) | WO2020089342A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230399390A1 (en) | 2019-10-24 | 2023-12-14 | Novago Therapeutics Ag | Novel anti-nogo-a antibodies |
| JP2023527163A (ja) * | 2020-05-19 | 2023-06-27 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 核酸送達用の脂質粒子およびその臨床応用 |
| US20230242624A1 (en) | 2020-06-02 | 2023-08-03 | Neurimmune Ag | HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) |
| WO2024003363A1 (en) * | 2022-06-30 | 2024-01-04 | Universiteit Gent | Cationic amphiphilic compound-based nanoparticle compositions |
| CN119486721A (zh) | 2022-07-08 | 2025-02-18 | 宝利普拉斯生物转染公司 | 包含基于咪唑鎓的阳离子脂质的脂质纳米颗粒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5627159A (en) | 1994-10-27 | 1997-05-06 | Life Technologies, Inc. | Enhancement of lipid cationic transfections in the presence of serum |
| FR2732895B1 (fr) * | 1995-04-11 | 1997-05-16 | Pasteur Merieux Serums Vacc | Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament |
| EP1129064B1 (en) | 1998-11-12 | 2008-01-09 | Invitrogen Corporation | Transfection reagents |
| US20040072769A1 (en) * | 2002-09-16 | 2004-04-15 | Yin James Qinwei | Methods for design and selection of short double-stranded oligonucleotides, and compounds of gene drugs |
| EP1844772A1 (en) | 2006-04-06 | 2007-10-17 | Polyplus-Transfection SA | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
| EP2860255A1 (en) * | 2013-10-14 | 2015-04-15 | Technische Universität Graz | Compositions comprising cationic and neutral lipids for transfecting nucleic acid molecules into eukaryotic cells |
| WO2016011203A1 (en) * | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
| ES2969956T3 (es) * | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| WO2017083403A1 (en) * | 2015-11-10 | 2017-05-18 | Children's Research Institute, Children's National Medical Center | Echinomycin formulation, method of making and method of use thereof |
-
2018
- 2018-10-30 PL PL18306417.9T patent/PL3646854T3/pl unknown
- 2018-10-30 DK DK18306417.9T patent/DK3646854T3/da active
- 2018-10-30 ES ES18306417T patent/ES2927532T3/es active Active
- 2018-10-30 EP EP18306417.9A patent/EP3646854B1/en active Active
- 2018-10-30 PT PT183064179T patent/PT3646854T/pt unknown
-
2019
- 2019-10-30 CN CN201980071624.3A patent/CN112930172B/zh active Active
- 2019-10-30 US US17/289,443 patent/US20210386841A1/en active Pending
- 2019-10-30 AU AU2019373387A patent/AU2019373387B2/en active Active
- 2019-10-30 KR KR1020217015096A patent/KR20210084511A/ko not_active Ceased
- 2019-10-30 SG SG11202103117RA patent/SG11202103117RA/en unknown
- 2019-10-30 JP JP2021525178A patent/JP7477504B2/ja active Active
- 2019-10-30 IL IL282579A patent/IL282579B2/en unknown
- 2019-10-30 WO PCT/EP2019/079742 patent/WO2020089342A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL3646854T3 (pl) | 2023-01-02 |
| IL282579B2 (en) | 2024-11-01 |
| SG11202103117RA (en) | 2021-04-29 |
| AU2019373387B2 (en) | 2025-04-17 |
| IL282579B1 (en) | 2024-07-01 |
| WO2020089342A1 (en) | 2020-05-07 |
| PT3646854T (pt) | 2022-09-27 |
| US20210386841A1 (en) | 2021-12-16 |
| CA3113877A1 (en) | 2020-05-07 |
| CN112930172A (zh) | 2021-06-08 |
| EP3646854B1 (en) | 2022-08-03 |
| AU2019373387A1 (en) | 2021-04-29 |
| KR20210084511A (ko) | 2021-07-07 |
| JP2022512983A (ja) | 2022-02-07 |
| ES2927532T3 (es) | 2022-11-08 |
| IL282579A (en) | 2021-06-30 |
| EP3646854A1 (en) | 2020-05-06 |
| JP7477504B2 (ja) | 2024-05-01 |
| CN112930172B (zh) | 2023-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3646854T3 (da) | Sammensætninger til transfektion af mRNA i en celle og anvendelser deraf | |
| DK3568494T3 (da) | Fremgangsmåder og sammensætninger til markering af celler | |
| IL280718A (en) | T cell receptor constructs and uses thereof | |
| IL270990A (en) | Expression of novel cell tags | |
| DK3963021T3 (da) | Stabiliserede fluorolefinsammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3553180T3 (da) | Fremgangsmåde til konstruktion af enkeltcellesekventeringsbibliotek og anvendelse deraf | |
| IL289124A (en) | Flow cells | |
| DK3399985T3 (da) | Sammensætninger og biblioteker, der omfatter rekombinante T-cellereceptorer, og fremgangsmåder til anvendelse af rekombinante T-cellereceptorer | |
| DK3471749T3 (da) | Fremgangsmåder og sammensætninger til detektering af en mål-RNA | |
| DK3368541T3 (da) | Sammensætninger og metoder til inhibiering af arginaseaktivitet | |
| DK3152312T3 (da) | Fremgangsmåder og sammensætninger til modifikation af et mållocus | |
| DK3048295T3 (da) | Fremgangsmåde til opførelse af en vindmølle og vindmølle | |
| DK3402483T3 (da) | Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler | |
| DK3880818T3 (da) | Nukleinsyrer til inhibering af ekspression af LPA i en celle | |
| DK3394272T3 (da) | Sammensætninger og fremgangsmåder til effektiv målretning af transgener | |
| DK3034870T3 (da) | Vindmølle med betontårn og fremgangsmåde til montage af vindmølle med betontårn | |
| EP3519578A4 (en) | COMPOSITIONS FOR TRANSFECTING TYPES OF RESISTANT CELLS | |
| DK3500661T3 (da) | Cellekulturindsats og anordning til kultivering af celler | |
| DK3607065T5 (da) | Fremgangsmåde og kit til konstruktion af nukleinsyrebibliotek | |
| DK3626814T3 (da) | Fremstilling af cellesfæroider | |
| DK3927899T3 (da) | Nedvibrering af funderinger | |
| DK3098298T3 (da) | Indretning til podning og dyrkning af celler | |
| IL284066A (en) | Flow cells | |
| DK3889374T3 (da) | Fremgangsmåde til konstruktion af bygninger | |
| DK3952003T3 (da) | Anordning til visning af batterirestværdi |